Limits...
Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis.

van Boven JF, van Raaij JJ, van der Galiën R, Postma MJ, van der Molen T, Dekhuijzen PN, Vegter S - NPJ Prim Care Respir Med (2014)

Bottom Line: Study outcomes were 1-year persistence and switching patterns.There was no significant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio: 0.98, 95% confidence interval: 0.76-1.26, P=0.99).Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers or medication within 1 year.

View Article: PubMed Central - PubMed

Affiliation: Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

ABSTRACT

Background: With a growing availability of different devices and types of medication, additional evidence is required to assist clinicians in prescribing the optimal medication in relation to chronic obstructive pulmonary disease (COPD) patients' persistence with long-acting β2-agonists (LABAs).

Aims: To assess the impact of the type of inhaler device (multiple-dose versus single-dose inhalers) on 1-year persistence and switching patterns with LABAs.

Methods: A retrospective observational cohort study was performed comparing a cohort of patients initiating multiple-dose inhalers and a cohort initiating single-dose inhalers. The study population consisted of long-acting bronchodilator naive COPD patients, initiating inhalation therapy with mono-LABAs (formoterol, indacaterol or salmeterol). Analyses were performed using pharmacy dispensing data from 1994 to 2012, obtained from the IADB.nl database. Study outcomes were 1-year persistence and switching patterns. RESULTS were adjusted for initial prescriber, initial medication, dosing regimen and relevant comorbidities.

Results: In all, 575 patients initiating LABAs were included in the final study cohort. Among them, 475 (83%) initiated a multiple-dose inhaler and 100 (17%) a single-dose inhaler. Further, 269 (47%) initiated formoterol, 9 (2%) indacaterol and 297 (52%) salmeterol. There was no significant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio: 0.98, 95% confidence interval: 0.76-1.26, P=0.99). Over 80% re-started or switched medication.

Conclusions: There seems no impact of inhaler device (multiple-dose versus single-dose inhalers) on COPD patients' persistence with LABAs. Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers or medication within 1 year.

Show MeSH

Related in: MedlinePlus

Flow diagram of the population selection process. Asthma patients, excluded based on use of antihistamines, anti-allergics, leukotriene receptor antagonists or omaluzimab; COPD, chronic obstructive pulmonary disease; double medication, initiating of two types of inhaled medication at the same date; DPI, dry powder inhaler; LABA, long-acting β2-agonist; pMDI, pressurised metered dose inhaler.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4373462&req=5

fig1: Flow diagram of the population selection process. Asthma patients, excluded based on use of antihistamines, anti-allergics, leukotriene receptor antagonists or omaluzimab; COPD, chronic obstructive pulmonary disease; double medication, initiating of two types of inhaled medication at the same date; DPI, dry powder inhaler; LABA, long-acting β2-agonist; pMDI, pressurised metered dose inhaler.

Mentions: A flow diagram is provided in Figure 1. Patient characteristics, per cohort, are presented in Table 1. Parameters that significantly differed (P<0.05) were the initial prescriber, comorbidities (lipid-metabolism disorders and psychosis, in particular), the initial medication and the dosing regimen.


Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis.

van Boven JF, van Raaij JJ, van der Galiën R, Postma MJ, van der Molen T, Dekhuijzen PN, Vegter S - NPJ Prim Care Respir Med (2014)

Flow diagram of the population selection process. Asthma patients, excluded based on use of antihistamines, anti-allergics, leukotriene receptor antagonists or omaluzimab; COPD, chronic obstructive pulmonary disease; double medication, initiating of two types of inhaled medication at the same date; DPI, dry powder inhaler; LABA, long-acting β2-agonist; pMDI, pressurised metered dose inhaler.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4373462&req=5

fig1: Flow diagram of the population selection process. Asthma patients, excluded based on use of antihistamines, anti-allergics, leukotriene receptor antagonists or omaluzimab; COPD, chronic obstructive pulmonary disease; double medication, initiating of two types of inhaled medication at the same date; DPI, dry powder inhaler; LABA, long-acting β2-agonist; pMDI, pressurised metered dose inhaler.
Mentions: A flow diagram is provided in Figure 1. Patient characteristics, per cohort, are presented in Table 1. Parameters that significantly differed (P<0.05) were the initial prescriber, comorbidities (lipid-metabolism disorders and psychosis, in particular), the initial medication and the dosing regimen.

Bottom Line: Study outcomes were 1-year persistence and switching patterns.There was no significant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio: 0.98, 95% confidence interval: 0.76-1.26, P=0.99).Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers or medication within 1 year.

View Article: PubMed Central - PubMed

Affiliation: Unit of PharmacoEpidemiology and PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

ABSTRACT

Background: With a growing availability of different devices and types of medication, additional evidence is required to assist clinicians in prescribing the optimal medication in relation to chronic obstructive pulmonary disease (COPD) patients' persistence with long-acting β2-agonists (LABAs).

Aims: To assess the impact of the type of inhaler device (multiple-dose versus single-dose inhalers) on 1-year persistence and switching patterns with LABAs.

Methods: A retrospective observational cohort study was performed comparing a cohort of patients initiating multiple-dose inhalers and a cohort initiating single-dose inhalers. The study population consisted of long-acting bronchodilator naive COPD patients, initiating inhalation therapy with mono-LABAs (formoterol, indacaterol or salmeterol). Analyses were performed using pharmacy dispensing data from 1994 to 2012, obtained from the IADB.nl database. Study outcomes were 1-year persistence and switching patterns. RESULTS were adjusted for initial prescriber, initial medication, dosing regimen and relevant comorbidities.

Results: In all, 575 patients initiating LABAs were included in the final study cohort. Among them, 475 (83%) initiated a multiple-dose inhaler and 100 (17%) a single-dose inhaler. Further, 269 (47%) initiated formoterol, 9 (2%) indacaterol and 297 (52%) salmeterol. There was no significant difference in persistence between users of multiple-dose or single-dose inhalers (hazard ratio: 0.98, 95% confidence interval: 0.76-1.26, P=0.99). Over 80% re-started or switched medication.

Conclusions: There seems no impact of inhaler device (multiple-dose versus single-dose inhalers) on COPD patients' persistence with LABAs. Over 80% of patients who initially seemed to discontinue LABAs, re-started their initial medication or switched inhalers or medication within 1 year.

Show MeSH
Related in: MedlinePlus